LMNL — Liminal BioSciences Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro Cap

Annual income statement for Liminal BioSciences, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.

	R2018 December 31st	R2019 December 31st	R2020 December 31st	2021 December 31st	2022 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	24.6	0.745	0.724	0.643	0.401
Cost of Revenue
Gross Profit	-1.07	—	—	—	—
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	256	147	47.9	50.5	33.4
Operating Profit	-232	-146	-47.2	-49.9	-33
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-259	-151	-49.2	-44.9	-29.4
Provision for Income Taxes
Net Income After Taxes	-240	-151	-49	-45.1	-28.9
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-195	-206	-118	12.9	0.5
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-195	-206	-118	12.9	0.5
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-1,470	-55.7	-20.2	-14.9	-9.34